# Bristol Myers Squibb Co: financial statements, quarterly

BMY · NYSE · CIK 14272 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bmy.md) · [Financials](/companies/bmy/financials.md) · [Filings](/companies/bmy/filings.md) · [Insiders](/companies/bmy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bmy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [11.0](/filings/0000014272-24-000147.md) | [11.5 d](/filings/0000014272-26-000004.md) | [11.9](/filings/0000014272-25-000091.md) | [12.2](/filings/0000014272-25-000131.md) | [11.9](/filings/0000014272-25-000149.md) | [12.3 d](/filings/0000014272-26-000004.md) | [11.2](/filings/0000014272-26-000010.md) | [12.3](/filings/0000014272-26-000020.md) | [12.2](/filings/0000014272-25-000149.md) | [12.5 d](/filings/0000014272-26-000004.md) | [11.5](/filings/0000014272-26-000010.md) | [13.0](/filings/0000014272-26-000020.md) |
| Cost of revenue | $bn | [2.5](/filings/0000014272-24-000147.md) | [2.7 d](/filings/0000014272-26-000004.md) | [2.9](/filings/0000014272-25-000091.md) | [3.3](/filings/0000014272-25-000131.md) | [3.0](/filings/0000014272-25-000149.md) | [4.8 d](/filings/0000014272-26-000004.md) | [3.0](/filings/0000014272-26-000010.md) | [3.4](/filings/0000014272-26-000020.md) | [3.4](/filings/0000014272-25-000149.md) | [4.1 d](/filings/0000014272-26-000004.md) | [3.4](/filings/0000014272-26-000010.md) | [3.7](/filings/0000014272-26-000020.md) |
| Gross profit | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $bn | [2.2](/filings/0000014272-24-000147.md) | [2.5 d](/filings/0000014272-26-000004.md) | [2.7](/filings/0000014272-25-000091.md) | [2.9](/filings/0000014272-25-000131.md) | [2.4](/filings/0000014272-25-000149.md) | [3.2 d](/filings/0000014272-26-000004.md) | [2.3](/filings/0000014272-26-000010.md) | [2.6](/filings/0000014272-26-000020.md) | [2.5](/filings/0000014272-25-000149.md) | [2.6 d](/filings/0000014272-26-000004.md) | [2.6](/filings/0000014272-26-000010.md) | [3.0](/filings/0000014272-26-000020.md) |
| Selling, general and administrative | $bn | [2.0](/filings/0000014272-24-000147.md) | [2.1 d](/filings/0000014272-26-000004.md) | [2.4](/filings/0000014272-25-000091.md) | [1.9](/filings/0000014272-25-000131.md) | [2.0](/filings/0000014272-25-000149.md) | [2.1 d](/filings/0000014272-26-000004.md) | [1.6](/filings/0000014272-26-000010.md) | [1.7](/filings/0000014272-26-000020.md) | [1.8](/filings/0000014272-25-000149.md) | [2.2 d](/filings/0000014272-26-000004.md) | [1.6](/filings/0000014272-26-000010.md) | [1.8](/filings/0000014272-26-000020.md) |
| Operating income | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $bn | [0.3](/filings/0000014272-23-000181.md) | [0.3 d](/filings/0000014272-24-000044.md) | [0.4](/filings/0000014272-24-000096.md) | [0.5](/filings/0000014272-25-000131.md) | [0.5](/filings/0000014272-25-000149.md) | [0.5 d](/filings/0000014272-26-000004.md) | [0.5](/filings/0000014272-26-000010.md) | [0.5](/filings/0000014272-26-000020.md) | [0.5](/filings/0000014272-25-000149.md) | [0.4 d](/filings/0000014272-26-000004.md) | [0.4](/filings/0000014272-26-000010.md) | [0.4](/filings/0000014272-26-000020.md) |
| Income tax | $bn | [0.2](/filings/0000014272-24-000147.md) | [(0.1) d](/filings/0000014272-26-000004.md) | [0.4](/filings/0000014272-25-000091.md) | [(0.4)](/filings/0000014272-25-000131.md) | [0.5](/filings/0000014272-25-000149.md) | [0.1 d](/filings/0000014272-26-000004.md) | [0.5](/filings/0000014272-26-000010.md) | [0.5](/filings/0000014272-26-000020.md) | [0.9](/filings/0000014272-25-000149.md) | [0.4 d](/filings/0000014272-26-000004.md) | [0.6](/filings/0000014272-26-000010.md) | [0.8](/filings/0000014272-26-000020.md) |
| Net income | $bn | [1.9](/filings/0000014272-24-000147.md) | [1.8 d](/filings/0000014272-26-000004.md) | [(11.9)](/filings/0000014272-25-000091.md) | [1.7](/filings/0000014272-25-000131.md) | [1.2](/filings/0000014272-25-000149.md) | [0.1 d](/filings/0000014272-26-000004.md) | [2.5](/filings/0000014272-26-000010.md) | [1.3](/filings/0000014272-26-000020.md) | [2.2](/filings/0000014272-25-000149.md) | [1.1 d](/filings/0000014272-26-000004.md) | [2.7](/filings/0000014272-26-000010.md) | [3.3](/filings/0000014272-26-000020.md) |
| Diluted EPS | $ per share | [0.93](/filings/0000014272-24-000147.md) | not reported | [(5.89)](/filings/0000014272-25-000091.md) | [0.83](/filings/0000014272-25-000131.md) | [0.60](/filings/0000014272-25-000149.md) | not reported | [1.20](/filings/0000014272-26-000010.md) | [0.64](/filings/0000014272-26-000020.md) | [1.08](/filings/0000014272-25-000149.md) | not reported | [1.31](/filings/0000014272-26-000010.md) | [1.62](/filings/0000014272-26-000020.md) |
| Basic EPS | $ per share | [0.94](/filings/0000014272-24-000147.md) | not reported | [(5.89)](/filings/0000014272-25-000091.md) | [0.83](/filings/0000014272-25-000131.md) | [0.60](/filings/0000014272-25-000149.md) | not reported | [1.21](/filings/0000014272-26-000010.md) | [0.64](/filings/0000014272-26-000020.md) | [1.08](/filings/0000014272-25-000149.md) | not reported | [1.31](/filings/0000014272-26-000010.md) | [1.62](/filings/0000014272-26-000020.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: not reported
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [7.5](/filings/0000014272-23-000181.md) | [11.5](/filings/0000014272-25-000039.md) | [9.3](/filings/0000014272-24-000096.md) | [6.3](/filings/0000014272-24-000123.md) | [7.9](/filings/0000014272-24-000147.md) | [10.3](/filings/0000014272-26-000004.md) | [10.9](/filings/0000014272-25-000091.md) | [12.6](/filings/0000014272-25-000131.md) | [15.7](/filings/0000014272-25-000149.md) | [10.2](/filings/0000014272-26-000020.md) | [9.6](/filings/0000014272-26-000010.md) | [8.7](/filings/0000014272-26-000020.md) |
| Current assets | $bn | [27.6](/filings/0000014272-23-000181.md) | [31.8](/filings/0000014272-25-000039.md) | [28.7](/filings/0000014272-24-000096.md) | [26.9](/filings/0000014272-24-000123.md) | [28.1](/filings/0000014272-24-000147.md) | [29.8](/filings/0000014272-26-000004.md) | [30.8](/filings/0000014272-25-000091.md) | [33.2](/filings/0000014272-25-000131.md) | [35.6](/filings/0000014272-25-000149.md) | [29.4](/filings/0000014272-26-000020.md) | [27.2](/filings/0000014272-26-000010.md) | [28.6](/filings/0000014272-26-000020.md) |
| Total assets | $bn | [91.3](/filings/0000014272-23-000181.md) | [95.2](/filings/0000014272-25-000039.md) | [99.0](/filings/0000014272-24-000096.md) | [94.6](/filings/0000014272-24-000123.md) | [93.7](/filings/0000014272-24-000147.md) | [92.6](/filings/0000014272-26-000004.md) | [92.4](/filings/0000014272-25-000091.md) | [94.7](/filings/0000014272-25-000131.md) | [96.9](/filings/0000014272-25-000149.md) | [90.0](/filings/0000014272-26-000020.md) | [86.5](/filings/0000014272-26-000010.md) | [87.6](/filings/0000014272-26-000020.md) |
| Current liabilities | $bn | [23.5](/filings/0000014272-23-000181.md) | [22.3](/filings/0000014272-25-000039.md) | [25.8](/filings/0000014272-24-000096.md) | [23.3](/filings/0000014272-24-000123.md) | [22.6](/filings/0000014272-24-000147.md) | [23.8](/filings/0000014272-26-000004.md) | [24.1](/filings/0000014272-25-000091.md) | [27.5](/filings/0000014272-25-000131.md) | [28.1](/filings/0000014272-25-000149.md) | [23.4](/filings/0000014272-26-000020.md) | [19.2](/filings/0000014272-26-000010.md) | [18.7](/filings/0000014272-26-000020.md) |
| Total liabilities | $bn | [62.2](/filings/0000014272-23-000181.md) | [65.7](/filings/0000014272-25-000039.md) | [82.5](/filings/0000014272-24-000096.md) | [77.6](/filings/0000014272-24-000123.md) | [76.5](/filings/0000014272-24-000147.md) | [76.2](/filings/0000014272-26-000004.md) | [75.0](/filings/0000014272-25-000091.md) | [77.2](/filings/0000014272-25-000131.md) | [78.3](/filings/0000014272-25-000149.md) | [71.5](/filings/0000014272-26-000020.md) | [66.4](/filings/0000014272-26-000010.md) | [65.3](/filings/0000014272-26-000020.md) |
| Long-term debt | $bn | [32.1](/filings/0000014272-23-000181.md) | [36.7](/filings/0000014272-25-000039.md) | [49.5](/filings/0000014272-24-000096.md) | [48.9](/filings/0000014272-24-000123.md) | [48.7](/filings/0000014272-24-000147.md) | [47.6](/filings/0000014272-26-000004.md) | [46.2](/filings/0000014272-25-000091.md) | [44.5](/filings/0000014272-25-000131.md) | [44.5](/filings/0000014272-25-000149.md) | [42.9](/filings/0000014272-26-000020.md) | [42.2](/filings/0000014272-26-000010.md) | [42.1](/filings/0000014272-26-000020.md) |
| Current portion of debt | $bn | [4.9](/filings/0000014272-23-000181.md) | [2.9](/filings/0000014272-25-000039.md) | [2.9](/filings/0000014272-24-000096.md) | [3.1](/filings/0000014272-24-000123.md) | [0.9](/filings/0000014272-24-000147.md) | [1.8](/filings/0000014272-26-000004.md) | [3.3](/filings/0000014272-25-000091.md) | [4.5](/filings/0000014272-25-000131.md) | [4.2](/filings/0000014272-25-000149.md) | [2.0](/filings/0000014272-26-000020.md) | [2.0](/filings/0000014272-26-000010.md) | [0.8](/filings/0000014272-26-000020.md) |
| Short-term borrowings | $bn | [5.5](/filings/0000014272-23-000181.md) | [3.1](/filings/0000014272-25-000039.md) | [6.2](/filings/0000014272-24-000096.md) | [3.5](/filings/0000014272-24-000123.md) | [1.1](/filings/0000014272-24-000147.md) | [2.0](/filings/0000014272-26-000004.md) | [3.6](/filings/0000014272-25-000091.md) | [4.7](/filings/0000014272-25-000131.md) | [4.5](/filings/0000014272-25-000149.md) | [2.3](/filings/0000014272-26-000020.md) | [2.3](/filings/0000014272-26-000010.md) | [1.0](/filings/0000014272-26-000020.md) |
| Shareholders' equity | $bn | [29.0](/filings/0000014272-23-000181.md) | [29.4](/filings/0000014272-25-000039.md) | [16.5](/filings/0000014272-24-000096.md) | [17.0](/filings/0000014272-24-000123.md) | [17.1](/filings/0000014272-24-000147.md) | [16.3](/filings/0000014272-26-000004.md) | [17.4](/filings/0000014272-25-000091.md) | [17.4](/filings/0000014272-25-000131.md) | [18.6](/filings/0000014272-25-000149.md) | [18.5](/filings/0000014272-26-000020.md) | [20.1](/filings/0000014272-26-000010.md) | [22.3](/filings/0000014272-26-000020.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4,751 d](/filings/0000014272-24-000147.md) | [4,252 d](/filings/0000014272-26-000004.md) | [2,834](/filings/0000014272-25-000091.md) | [2,326 d](/filings/0000014272-25-000131.md) | [5,591 d](/filings/0000014272-25-000149.md) | [4,439 d](/filings/0000014272-26-000004.md) | [1,954](/filings/0000014272-26-000010.md) | [3,917 d](/filings/0000014272-26-000020.md) | [6,311 d](/filings/0000014272-25-000149.md) | [1,974 d](/filings/0000014272-26-000004.md) | [1,104](/filings/0000014272-26-000010.md) | [3,393 d](/filings/0000014272-26-000020.md) |
| Capital expenditure | $m | [342 d](/filings/0000014272-24-000147.md) | [330 d](/filings/0000014272-26-000004.md) | [284](/filings/0000014272-25-000091.md) | [262 d](/filings/0000014272-25-000131.md) | [324 d](/filings/0000014272-25-000149.md) | [378 d](/filings/0000014272-26-000004.md) | [260](/filings/0000014272-26-000010.md) | [361 d](/filings/0000014272-26-000020.md) | [320 d](/filings/0000014272-25-000149.md) | [370 d](/filings/0000014272-26-000004.md) | [347](/filings/0000014272-26-000010.md) | [305 d](/filings/0000014272-26-000020.md) |
| Dividends paid | $m | [1,191 d](/filings/0000014272-24-000147.md) | [1,160 d](/filings/0000014272-26-000004.md) | [1,212](/filings/0000014272-25-000091.md) | [1,217 d](/filings/0000014272-25-000131.md) | [1,216 d](/filings/0000014272-25-000149.md) | [1,218 d](/filings/0000014272-26-000004.md) | [1,258](/filings/0000014272-26-000010.md) | [1,262 d](/filings/0000014272-26-000020.md) | [1,263 d](/filings/0000014272-25-000149.md) | [1,262 d](/filings/0000014272-26-000004.md) | [1,283](/filings/0000014272-26-000010.md) | [1,287 d](/filings/0000014272-26-000020.md) |
| Share repurchases | $m | [4,000 d](/filings/0000014272-24-000147.md) | [0.0 d](/filings/0000014272-26-000004.md) | [0.0](/filings/0000014272-24-000096.md) | [0.0 d](/filings/0000014272-24-000123.md) | [0.0 d](/filings/0000014272-24-000147.md) | [0.0 d](/filings/0000014272-26-000004.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2,148](/filings/0000014272-23-000181.md) | [2,113](/filings/0000014272-24-000096.md) | [2,102](/filings/0000014272-24-000123.md) | [2,064](/filings/0000014272-24-000147.md) | [2,023](/filings/0000014272-25-000091.md) | [2,029](/filings/0000014272-25-000131.md) | [2,031](/filings/0000014272-25-000149.md) | [2,040](/filings/0000014272-26-000010.md) | [2,038](/filings/0000014272-26-000020.md) | [2,039](/filings/0000014272-25-000149.md) | [2,047](/filings/0000014272-26-000010.md) | [2,048](/filings/0000014272-26-000020.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,042,714,656 at 2026-07-22, from the cover of the [10-Q filed 2026-07-30](/filings/0000014272-26-000020.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.